as attached
ERIS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 10.1 pts more than Nifty Smallcap 250 and 9.9 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Eris Lifesciences reported audited consolidated results for FY2026 ending March 31. Total revenue from operations grew 8.1% to Rs 3,129.42 crore from Rs 2,893.64 crore. Net profit surged 72.8% to Rs 647.51 crore vs Rs 374.67 crore, driven partly by a deferred tax credit of Rs 150 crore from the new Income Tax Act 2025 concessional regime and Rs 17.24 crore exceptional item (increase in gratuity/leave liability from new labour codes). Operating margin expanded to 27.1% from 24.9% a year ago. The Board declared an interim dividend of Rs 7.21 per share (721% on Re. 1 face value). Auditors Walker Chandiok & Co LLP issued unmodified opinions on both standalone and consolidated financials with no qualifications. The company completed acquisition of Swiss Parenterals (now wholly-owned subsidiary) and the branded probiotics business from Velbiom for Rs 50 crore.
Strong bottom-line growth driven by tax benefits and margin expansion is positive for shareholders. The healthy dividend declaration reinforces investor confidence. However, the standalone entity showed a loss in Q4 due to higher costs, which warrants monitoring.